Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

In multicellular organisms, angiogenesis, the formation of new blood vessels from pre-
existing ones, is an essential process for growth and development. Different mechanisms …

BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …

Blood vessel endothelial cells (ECs) have long been known to modulate inflammation by
regulating immune cell trafficking, activation status and function. However, whether the …

The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the
treatment of advanced cancers. However, the tumor microenvironment (TME) functions as a …

Tumor vascularization occurs through several distinct biological processes, which not only
vary between tumor type and anatomic location, but also occur simultaneously within the …

Immune checkpoint inhibitors have revolutionized medical oncology, although currently only
a subset of patients has a response to such treatment. A compelling body of evidence …

Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-
lymphoid tissues at sites of chronic inflammation including tumours. Key common …